The FDA has approved Exdensur (depemokimab-ulaa) as an add-on maintenance treatment for people with severe asthma.

The MHRA has approved depemokimab as an add-on treatment for severe asthma and chronic rhinosinusitis with nasal polyps.

The negotiated prices are a result of a program passed by Congress in 2022 as part of the Inflation Reduction Act (IRA). The measure lowers prescription drug costs for seniors by empowering Medicare ...

For many, these price reductions may represent a critical step in improving access to essential medications, especially as ...

The Trump administration has negotiated lower prices for 15 widely used medications covered by Medicare, with the federal government saying the effort will cut spending on those drugs by 44%, or about ...

As with any medicine, the MHRA will keep the safety and effectiveness of depemokimab under close review. The Medicines and Healthcare products ...

The Trump administration has negotiated lower prices for 15 widely used medications covered by Medicare, with the federal government saying the effort will cut spending on those drugs by 44%, or about ...

Povorcitinib is a selective oral small-molecule JAK1 inhibitor, with compound and use patents in certain countries/regions in the Territory. Currently, povorcitinib is in Phase 3 clinical trials for ...

STUART, Fla., Dec. 16, 2025 /PRNewswire/ -- The United States is entering a period of significant disruption in healthcare coverage, according to health policy observers, with millions of Americans ...

It's once again the time of year for an uptick in illnesses such as colds, the flu, COVID and RSV. Here are the signs and ...

Eli Lilly cuts cash prices for Zepbound weight-loss vials on LillyDirect, offering doses from $299 to $449 as demand for ...

Tezepelumab reduced exacerbations across all seasons in severe uncontrolled asthma, even among patients with perennial and seasonal allergies.